On Thursday, the firm announced that it has reached an agreement with the California Institute for Regenerative Medicine through which CIRM will provide around $19.3 million to help fund preclinical development and IND-enabling activities of the Company's proprietary HuCNS-SC product candidate for Alzheimer's disease.
http://wallstcheatsheet.com/stocks/3-healthcare-stock-stories-for-thursday-enjoyment.html/
http://wallstcheatsheet.com/stocks/3-healthcare-stock-stories-for-thursday-enjoyment.html/
No comments:
Post a Comment